MTOR and COVID-19: Early studies suggested that mTOR inhibitors like Sirolimus could reduce SARS-CoV-2 replication and suppress immune responses and cytokine storms, positing that it might be a potential strategy for mitigating the severity of COVID-19 (26–29).